Industry warming to more user-friendly FDA inspections
This article was originally published in Clinica
Like paying taxes, FDA plant inspections have typically been something to endure - an unpleasant but necessary burden. But a new survey conducted by an FDA/industry committee under the auspices of the Medical Device Industry Initiatives Grassroots Task Force suggests companies are changing their minds about the FDA inspection process.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.